#SYNERON CANDELA IRVINE CA UPDATE#

The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance. Irvine, CA 92618 USA +1 (949) 830-5409 telephone +1 (949) 830-8944 facsimile Email:.

These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. (NASDAQ: ELOS), a leading global non-surgical aesthetic device company, and Apax Partners, a leading global private equity advisory firm, today announced a definitive agreement under which an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for 11.00 per share in cash in a. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Irvine, CA and London, Ap Syneron Medical Ltd. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, market acceptance of new products, and projected revenues, margins, earnings and market shares. Using this technology, he went on to develop devices that were used to treat birthmarks, kidney stones and glaucoma.This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. 1 Prospective data from Natrelles (Allergan, Inc., Irvine, CA) Style 410 silicone-filled implant study revealed a 4.7 rate of malposition within 10 years of primary augmentation and a 9.1 rate of malposition following revision augmentation. Furomoto invented the world’s first high-power dye laser and in 1982, along with other distinguished physicians, developed the principles of selective photothermolysis. Implant malposition is among the most common reasons for revisionary breast surgery.

Founded in 1970 by Horace Furumoto, an advanced scientist and physicist, Candela has based its’ development approach on scientific study and innovation which in turn, has made us a global leader in energy-based devices. While beauty may be in the eye of the beholder, here at Candela, we believe that the way to achieve beautiful results is through science. We offer an extensive product portfolio with technology that enables physicians to provide a wide range of advanced solutions for improving the skin's appearance. For close to 50 years, Candela has been a leading global medical aesthetic device company.

Syneron candela irvine ca